SCHEMBL23217430

SCHEMBL23217430

COc1ccc(Cl)c(Cl)c1CC(C)=C[C@H]1CCN(C(=O)O)C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.38
DRD2 P14416 2/20 0.38
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ITGB2 P05107 1/20 0.33
ICAM1 P05362 1/20 0.33
ITGAL P20701 1/20 0.33
PKM P14618 1/20 0.33
LMNA P02545 2/20 0.32
NPC1 O15118 1/20 0.32
APOBEC3A P31941 1/20 0.32
RAB9A P51151 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PDE4B Q07343 1/20 0.32
OPRD1 P41143 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217162 0.79 ALDH1A1 (0.38) S1PR1DRD2ALDH1A1PKMLMNA
SCHEMBL23217213 0.74 DRD2 (0.36) S1PR1DRD2GAAMAPTALDH1A1
SCHEMBL23216508 0.73 SMN1; SMN2 (0.45) ALDH1A1LMNANPC1APOBEC3AAPOBEC3G
SCHEMBL28827794 0.69 ALDH1A1 (0.37) DRD2MAPTALDH1A1PKMLMNA
SCHEMBL28827789 0.68 MAPT (0.39) DRD2GAAMAPTALDH1A1LMNA
SCHEMBL23217050 0.67 LMNA (0.37) DRD2MAPTALDH1A1ITGB2ICAM1
SCHEMBL28827759 0.66 DRD2 (0.37) DRD2GAAMAPTALDH1A1PKM
SCHEMBL23214820 0.64 SMN1; SMN2 (0.42) ALDH1A1LMNANPC1MEN1KMT2A
SCHEMBL23217318 0.63 HTR2C (0.41) DRD2ALDH1A1PKMPDE4B
SCHEMBL23230438 0.62 PDE7A (0.40) DRD2ALDH1A1PKMLMNAAPOBEC3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114828963-A Arylheterobicyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-29 CN disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 S1PR1 1325/4885DRD2 1975/4885GAA 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.